Ironwood Pharmaceuticals Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.ironwoodpharma.com

Earnings Score
Safety Score

Market Cap $544.72M
Debt $206.00M
Cash $88.21M
EV $662.51M
FCF $123.82M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$3.12M
EBIT	$94.63M
ROA	24%
FCF	$123.82M
Equity	-$311.33M
Growth Stability	-382%
PE	-174.53
PEG	93.68
PB	-1.75
P/FCF	4.4
P/S	1.44
Price/Cash	0.16
Debt/Equity	-0.66
Debt/FCF	1.66
Net Margins	-1%
Op. Margins	25%
Earnings CAGR	-0%
Sales Growth YoY	-19%
Sales Growth QoQ	-3%
Sales CAGR	9%
FCF CAGR	4%
Equity CAGR	7%
Earnings Stability	0
Earnings Growth YoY	-74%

Earnings Growth QoQ	-524%
Earnings CAGR 5Y	-2%
Sales CAGR 5Y	-0%
FCF CAGR 5Y	28%
Equity CAGR 5Y	12%
Earnings CAGR 3Y	-1%
Sales CAGR 3Y	-1%
FCF CAGR 3Y	-27%
Equity CAGR 3Y	1%
Market Cap	$544.72M
Revenue	$378.42M
Assets	$389.52M
Total Debt	$206.00M
Cash	$88.21M
Shares Outstanding	158.81M
EV	662.51M
Earnings Score	6%
Safety Score	33%
Working Capital	129.22M
Current Ratio	3.62
Shares Growth 3y	0%
Equity Growth QoQ	-3%
Equity Growth YoY	-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

SEC Filings

Direct access to Ironwood Pharmaceuticals Inc (IRWD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Ironwood Pharmaceuticals Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ironwood Pharmaceuticals Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%

Stability 0%

loading chart...

Ironwood Pharmaceuticals Inc Discounted Cash Flow

Fully customizable DCF calculator online for Ironwood Pharmaceuticals Inc.

Years

Calculation mode

= $1.6B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$124M	$128M	$133M	$138M	$143M	$149M	$154M	$160M	$166M	$172M	$179M	$1.8B
DCF		$117M	$110M	$104M	$98M	$92M	$87M	$82M	$78M	$73M	$69M	$690M
Value	$1.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-248%	-95%	-30%	-39%	-81%	5%	27%	128%	43%	-233%	-1%
ROA	-	-16%	-7%	-13%	-58%	30%	26%	21%	23%	-201%	24%
ROE	-	-150%	-122%	-1K%	144%	-23%	170%	87%	27%	298%	-

Bad Net Margins (-0.53%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-3.25	-	-2.4	-3.94	115.38	3.27	2.51	1.51	3.26	1.66
Debt over Equity	0.13	3.79	-	25.3	-1.59	-4.38	8.72	1.08	0.63	-1.73	-0.66
Growth Stability	-	-	-	-	-	-	-	-	80%	-382%	-382%

Good Debt/FCF ratio (1.66)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.66)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-382%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	96%	83%	9%	16%	24%	-9%	6%	-1%	8%	-0%
Earnings YoY growth	-	-25%	-43%	43%	141%	-108%	394%	398%	-67%	-689%	-2%
Equity YoY growth	-	7%	-30%	-85%	-2K%	-53%	-167%	867%	8%	-153%	12%
FCF YoY growth	-	-30%	-73%	250%	-23%	-104%	5K%	57%	5%	-33%	28%